Do analysts prefer LIAN or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer LIAN or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, LIAN or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is LIAN or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Polyrizon N/A N/A N/A

Do analysts rate BGM or LIAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, BGM or LIAN?

BGM Group has higher revenue and earnings than LianBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $47.90M 0.53 -$19.94M N/A N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is BGM or LIAN more profitable?

BGM Group's return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A LianBio N/A -33.17% -30.19%

Do analysts prefer LIAN or ACTU?

Actuate Therapeutics has a consensus price target of $10.50, indicating a potential upside of 1,453.25%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings & valuation, LIAN or ACTU?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A

Is LIAN or ACTU more profitable?

LianBio's return on equity of -33.17% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Actuate Therapeutics N/A -346.19% -178.40%

Do analysts rate LIAN or TVRD?

Tvardi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 1,299.69%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has better valuation & earnings, LIAN or TVRD?

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Tvardi Therapeutics N/A N/A -$18.21M -$2.79 N/A

Is LIAN or TVRD more profitable?

LianBio's return on equity of -33.17% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Tvardi Therapeutics N/A -145.40% -91.11%

LianBio (LIAN) Competitors

$0.06 0.00 (0.00%)

As of 09/23/2026

Compare

LIAN vs. TXMD, PLRZ, BGM, ACTU, and TVRD

Should you buy LianBio stock or one of its competitors? LianBio's main competitors and comparable companies include TherapeuticsMD (TXMD), Polyrizon (PLRZ), BGM Group (BGM), Actuate Therapeutics (ACTU), and Tvardi Therapeutics (TVRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LianBio compare to TherapeuticsMD?

LianBio (NASDAQ:LIAN) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

LianBio has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

74.8% of LianBio shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TherapeuticsMD has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
TherapeuticsMD	$3.02M	8.31	-$570K	$0.02	108.50

In the previous week, LianBio's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats LianBio on 8 of the 11 factors compared between the two stocks.

How does LianBio compare to Polyrizon?

LianBio (NASDAQ:LIAN) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Polyrizon's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Polyrizon	N/A	N/A	N/A

LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.39, meaning that its share price is 239% less volatile than the broader market.

In the previous week, Polyrizon had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Polyrizon and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 equaled Polyrizon'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Polyrizon	Neutral

Summary

Polyrizon beats LianBio on 5 of the 8 factors compared between the two stocks.

How does LianBio compare to BGM Group?

BGM Group (NASDAQ:BGM) and LianBio (NASDAQ:LIAN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

74.8% of LianBio shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BGM Group has higher revenue and earnings than LianBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$47.90M	0.53	-$19.94M	N/A	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

BGM Group's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
LianBio	N/A	-33.17%	-30.19%

In the previous week, BGM Group's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
BGM Group	Neutral
LianBio	Neutral

BGM Group has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Summary

BGM Group beats LianBio on 7 of the 8 factors compared between the two stocks.

How does LianBio compare to Actuate Therapeutics?

LianBio (NASDAQ:LIAN) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Actuate Therapeutics has a consensus price target of $10.50, indicating a potential upside of 1,453.25%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Actuate Therapeutics' average media sentiment score of 1.01 beat LianBio's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Actuate Therapeutics	Positive

LianBio's return on equity of -33.17% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Actuate Therapeutics	N/A	-346.19%	-178.40%

Summary

Actuate Therapeutics beats LianBio on 7 of the 12 factors compared between the two stocks.

How does LianBio compare to Tvardi Therapeutics?

LianBio (NASDAQ:LIAN) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

74.8% of LianBio shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Tvardi Therapeutics had 3 more articles in the media than LianBio. MarketBeat recorded 3 mentions for Tvardi Therapeutics and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 equaled Tvardi Therapeutics'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Tvardi Therapeutics	Neutral

Tvardi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 1,299.69%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

LianBio's return on equity of -33.17% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A

Summary

Tvardi Therapeutics beats LianBio on 7 of the 13 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIAN vs. The Competition

Export

Metric	LianBio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.43M	$12.62B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.07	797.33	274.92	25.63
Price / Sales	N/A	852.31	673.28	90.00
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.02	10.60	10.34	6.27
Net Income	-$110.29M	$2.84B	$3.49B	$360.12M
7 Day Performance	N/A	-0.78%	-1.13%	-0.31%
1 Month Performance	N/A	-1.63%	-3.55%	-3.67%
1 Year Performance	N/A	2.51%	14.81%	5.14%

LianBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIAN LianBio	N/A	$0.06 flat	N/A	N/A	$6.43M	N/A	N/A	110
TXMD TherapeuticsMD	0.7552 of 5 stars	$2.18 +0.9%	N/A	+102.8%	$25M	$3.02M	109.00	420	Positive News
PLRZ Polyrizon	0.683 of 5 stars	$10.65 -6.5%	N/A	+72.2%	$24.37M	N/A	N/A	N/A
BGM BGM Group	0.7616 of 5 stars	$0.26 +4.3%	N/A	-97.8%	$24.03M	$37.92M	N/A	298
ACTU Actuate Therapeutics	2.907 of 5 stars	$1.00 +1.4%	$10.50 +952.7%	-89.4%	$23.62M	N/A	N/A	10	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIAN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LianBio (LIAN) Competitors

LIAN vs. TXMD, PLRZ, BGM, ACTU, and TVRD

How does LianBio compare to TherapeuticsMD?

Summary

How does LianBio compare to Polyrizon?

Summary

How does LianBio compare to BGM Group?

Summary

How does LianBio compare to Actuate Therapeutics?

Summary

How does LianBio compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LianBio (LIAN) Competitors

LIAN vs. TXMD, PLRZ, BGM, ACTU, and TVRD

How does LianBio compare to TherapeuticsMD?

Is LIAN or TXMD more profitable?

Which has more risk & volatility, LIAN or TXMD?

Do analysts prefer LIAN or TXMD?

Do institutionals & insiders hold more shares of LIAN or TXMD?

Which has higher earnings & valuation, LIAN or TXMD?

Does the media refer more to LIAN or TXMD?

Summary

How does LianBio compare to Polyrizon?

Do analysts prefer LIAN or PLRZ?

Which has stronger earnings and valuation, LIAN or PLRZ?

Do institutionals and insiders hold more shares of LIAN or PLRZ?

Is LIAN or PLRZ more profitable?

Which has more risk and volatility, LIAN or PLRZ?

Does the media refer more to LIAN or PLRZ?

Summary

How does LianBio compare to BGM Group?

Do institutionals and insiders believe in BGM or LIAN?

Do analysts rate BGM or LIAN?

Which has preferable valuation and earnings, BGM or LIAN?

Is BGM or LIAN more profitable?

Does the media refer more to BGM or LIAN?

Which has more volatility & risk, BGM or LIAN?

Summary

How does LianBio compare to Actuate Therapeutics?

Do analysts prefer LIAN or ACTU?

Which has more risk & volatility, LIAN or ACTU?

Which has better earnings & valuation, LIAN or ACTU?

Do institutionals & insiders believe in LIAN or ACTU?

Does the media prefer LIAN or ACTU?

Is LIAN or ACTU more profitable?

Summary

How does LianBio compare to Tvardi Therapeutics?

Do institutionals & insiders hold more shares of LIAN or TVRD?

Does the media prefer LIAN or TVRD?

Do analysts rate LIAN or TVRD?

Is LIAN or TVRD more profitable?

Which has more volatility and risk, LIAN or TVRD?

Which has better valuation & earnings, LIAN or TVRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools